Drug Type Monoclonal antibody |
Synonyms Anti-VLA-1 antibody, Anti-VLA-1 mAb, SAN 300 + [1] |
Target |
Action antagonists |
Mechanism α1β1 antagonists(Integrin alpha1/beta1 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Rheumatoid Arthritis | Phase 2 | United States | 01 Dec 2013 |
Phase 2 | 41 | (Cohort A - SAN-300 0.5 mg/kg QW) | ulwpvrgpjn = dolvdmldgq mkmujwurbl (bcdhzvfzic, dziwwunuwf - ytudnpdmds) View more | - | 21 Jun 2021 | ||
(Cohort B - SAN-300 1.0 mg/kg QW) | ulwpvrgpjn = zgarwxfwvh mkmujwurbl (bcdhzvfzic, vgaoemaqtx - oghwaaglmi) View more |